150 related articles for article (PubMed ID: 2880862)
1. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states.
Petraglia F; De Leo V; Nappi C; Facchinetti F; Montemagno U; Brambilla F; Genazzani AR
J Clin Endocrinol Metab; 1987 Mar; 64(3):508-12. PubMed ID: 2880862
[TBL] [Abstract][Full Text] [Related]
2. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121
[TBL] [Abstract][Full Text] [Related]
3. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia.
Cook CB; Nippoldt TB; Kletter GB; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525
[TBL] [Abstract][Full Text] [Related]
4. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 Mar; 50(3):427-30. PubMed ID: 7358828
[TBL] [Abstract][Full Text] [Related]
5. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic opioid antagonism on the hypothalamic-pituitary-ovarian axis in hyperprolactinemic women.
Matera C; Freda PU; Ferin M; Wardlaw SL
J Clin Endocrinol Metab; 1995 Feb; 80(2):540-5. PubMed ID: 7852517
[TBL] [Abstract][Full Text] [Related]
7. Catecholamines and pituitary function. VII: Effects of acute and chronic dopamine-receptor blockade on pituitary response to TRH-GNRH in normal women and in patients with hyperprolactinemic amenorrhea.
Giammartino C; Ambrosi F; Pelicci G; Pagliacci MC; Fedeli L; Nicoletti I
Horm Metab Res; 1988 Jan; 20(1):44-8. PubMed ID: 3131222
[TBL] [Abstract][Full Text] [Related]
8. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia decreases the luteinizing hormone-releasing hormone concentration in pituitary portal plasma: a possible role for beta-endorphin as a mediator.
Sarkar DK; Yen SS
Endocrinology; 1985 May; 116(5):2080-4. PubMed ID: 3157564
[TBL] [Abstract][Full Text] [Related]
10. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion.
Baranowska B; Rozbicka G; Jeske W; Abdel-Fattah MH
J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696
[TBL] [Abstract][Full Text] [Related]
11. A possible role of endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human.
Veldhuis JD; Worgul TJ; Monsaert R; Hammond JM
J Endocrinol Invest; 1981; 4(1):31-6. PubMed ID: 7240669
[TBL] [Abstract][Full Text] [Related]
12. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women.
Reid RL; Quigley ME; Yen SS
J Clin Endocrinol Metab; 1983 Dec; 57(6):1107-10. PubMed ID: 6313728
[TBL] [Abstract][Full Text] [Related]
13. Constancy of opioid control of luteinizing hormone in different pathophysiological states.
Lightman SL; Jacobs HS; Maguire AK; McGarrick G; Jeffcoate SL
J Clin Endocrinol Metab; 1981 Jun; 52(6):1260-3. PubMed ID: 6785301
[TBL] [Abstract][Full Text] [Related]
14. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine.
Sauder SE; Frager M; Case GD; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1984 Nov; 59(5):941-8. PubMed ID: 6434588
[TBL] [Abstract][Full Text] [Related]
15. The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman.
Verhelst J; Beckers A; Abs R
Fertil Steril; 1995 Nov; 64(5):969-71. PubMed ID: 7589643
[TBL] [Abstract][Full Text] [Related]
16. The effect of hyperprolactinemia produced by transplantable pituitary MtTW15 tumor cells in male rats on hypothalamic luteinizing hormone-releasing hormone release in vitro: effects of naloxone and K+.
Kalra PS; Kalra SP
Endocrinology; 1987 Jul; 121(1):310-5. PubMed ID: 3297642
[TBL] [Abstract][Full Text] [Related]
17. Altered neuroendocrine regulation of luteinizing hormone secretion in postmenopausal women with Parkinson's disease.
Cagnacci A; Melis GB; Soldani R; Bonuccelli U; Piccini P; Napolitano A; Muratorio A; Fioretti P
Neuroendocrinology; 1991 Jun; 53(6):549-55. PubMed ID: 1678880
[TBL] [Abstract][Full Text] [Related]
18. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
19. Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women.
Fioretti P; Cagnacci A; Paoletti AM; Gambacciani M; Soldani R; Mauro GA; Spinetti A; Melis GB
J Endocrinol Invest; 1989 May; 12(5):295-301. PubMed ID: 2549113
[TBL] [Abstract][Full Text] [Related]
20. Opioid-dopaminergic interactions in primary empty sella.
Mancini A; Conte G; Fiumara C; Fabrizi ML; Iacona T; Zuppi P; Colosimo C; De Marinis L
Exp Clin Endocrinol; 1993; 101(5):277-82. PubMed ID: 8299703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
